NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

The problem with a statement like the improvement is 3+ months, that's where the survivors hit the 50% point. What would the benefit be if you took all the patients at the current point in their lives. I suspect that there are people who were some of the first in the trial who're still alive, many with 10 years or more. I think that longevity is far more important than when we went below 50% surviving. If we took the average life span of all the patients it would still be growing as many of them just keep adding years.

Gary